KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer Review

  


Authors: Bang, Y. J.; Van Cutsem, E.; Fuchs, C. S.; Ohtsu, A.; Tabernero, J.; Ilson, D. H.; Hyung, W. J.; Strong, V. E.; Goetze, T. O.; Yoshikawa, T.; Tang, L. H.; Hwang, P. M. T.; Webb, N.; Adelberg, D.; Shitara, K.
Review Title: KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
Abstract: Background: Surgical resection is the only curative treatment option for gastric cancer. Despite widespread adoption of multimodality perioperative treatment strategies, 5-year overall survival rates remain low. In patients with advanced gastric or gastroesophageal junction adenocarcinoma, pembrolizumab has demonstrated promising efficacy and manageable safety as monotherapy in previously treated patients and as first-line therapy in combination with cisplatin and 5-fluorouracil. Combining chemotherapy with pembrolizumab in the neoadjuvant/adjuvant setting may benefit patients with locally advanced, resectable disease. Aim: To describe the design and rationale for the global, multicenter, randomized, double-blind, Phase III KEYNOTE-585 study to evaluate the efficacy and safety of pembrolizumab plus chemotherapy compared with placebo plus chemotherapy as neoadjuvant/adjuvant treatment for localized gastric or gastroesophageal junction adenocarcinoma. ClinicalTrials.gov: NCT0322142. © 2019 Future Medicine Ltd.
Keywords: adjuvant therapy; neoadjuvant therapy; chemotherapy; immunotherapy; surgery; gastric cancer; gastroesophageal junction cancer; pembrolizumab
Journal Title: Future Oncology
Volume: 15
Issue: 9
ISSN: 1479-6694
Publisher: Future Medicine  
Date Published: 2019-03-01
Start Page: 943
End Page: 952
Language: English
DOI: 10.2217/fon-2018-0581
PUBMED: 30777447
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063237152&doi=10.2217%2ffon-2018-0581&partnerID=40&md5=c7bfc4b938b91569f1684bb224c54366
Notes: Article -- Export Date: 1 April 2019 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Laura Hong Tang
    447 Tang
  2. Vivian Strong
    264 Strong
  3. David H Ilson
    433 Ilson
Related MSK Work